For HER2 + BC patients exhibiting the H-cell phenotype, our use of FRET technology [35] to observe the formation of HNMT/HER2 complexes has shown promise in predicting a positive response to anti-HER2 treatment (Fig. 2I). Here, ERBB2 is linked to breast cancer.